Use of G-CSF in matched sibling donor pediatric allogeneic transplantation: A consensus statement from the Children's Oncology Group (COG) Transplant Discipline Committee and Pediatric Blood and Marrow Transplant Consortium (PBMTC) Executive Committee

Stephan A. Grupp, Haydar Frangoul, Donna Wall, Michael A. Pulsipher, John E. Levine, Kirk R. Schultz

Research output: Contribution to journalReview articlepeer-review

41 Scopus citations

Abstract

Preliminary studies indicate that G-CSF-primed marrow harvesting may result in a graft with increased mononuclear cells collected, increased CD34+ stem and progenitor cell dose and a potential for more rapid engraftment. Increased cell dose plus other potential positive effects of G-CSF priming have resulted in improved survival in non-randomized preliminary studies. These benefits may be available without the increased risk of chronic graft versus host disease (GVHD) that is experienced with allogeneic peripheral blood stem cell (PBSC) transplant. A phase III Children's Oncology Group (COG)/Pediatric Blood and Marrow Transplant Consortium (PBMTC) trial comparing G-CSF-primed marrow to standard marrow has been proposed. This document reviews background studies of G-CSF-primed marrow and addresses benefits and risks of G-CSF administration to normal pediatric donors. We conclude that the approach is promising and warrants further study. Risks of G-CSF to the donor are minimal and benefits to both donor and recipient may occur.

Original languageEnglish
Pages (from-to)414-421
Number of pages8
JournalPediatric Blood and Cancer
Volume46
Issue number4
DOIs
StatePublished - Apr 2006
Externally publishedYes

Keywords

  • Ethics of bone marrow donation
  • Granulocyte colony stimulation factor-primed bone marrow
  • Pediatric bone marrow transplantation
  • Pediatric donor safety

Fingerprint

Dive into the research topics of 'Use of G-CSF in matched sibling donor pediatric allogeneic transplantation: A consensus statement from the Children's Oncology Group (COG) Transplant Discipline Committee and Pediatric Blood and Marrow Transplant Consortium (PBMTC) Executive Committee'. Together they form a unique fingerprint.

Cite this